1. Publication
- Title: Ivermectin for Critically and Noncritically Ill Hospitalized Patients With COVID-19: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP)
- Acronym: REMAP-CAP Ivermectin Domain
- Year & Journal: Critical Care Medicine, epublished May 8, 2026 (2026;54(7):1546-1562)
- Citation: Hashmi M, Haniffa R, Jayakumar D, et al; REMAP-CAP Investigators. Ivermectin for Critically and Noncritically Ill Hospitalized Patients With COVID-19: REMAP-CAP. Crit Care Med. 2026;54(7):1546-1562. doi:10.1097/CCM.0000000000007134
2. Context & Rationale
Background: Ivermectin is an inexpensive antiparasitic with in vitro SARS-CoV-2 inhibition, but concentrations required for antiviral effect were difficult to achieve safely with standard human dosing. Despite this, ivermectin became widely promoted and used during the pandemic in some settings, especially outpatient, despite limited, heterogeneous evidence. Major outpatient RCTs (e.g., TOGETHER) were consistently negative; critically ill and hospitalized patients were under-represented in prior evidence.
Research Question/Hypothesis: Does ivermectin improve outcomes (organ support-free days and hospital survival) for critically and noncritically ill hospitalized patients with COVID-19?
Why This Matters: Given ivermectin's massive off-label uptake despite an evidence gap specifically in hospitalized/critically ill patients, a rigorous, adequately-designed platform trial was needed to definitively test the hypothesis in this specific population.
3. Design & Methods
- Study Type: Ongoing international, multifactorial, adaptive platform, randomized, open-label, controlled trial (embedded within REMAP-CAP)
- Setting & Centers: Hospitals in Pakistan, India, and Ireland; enrolled June 11, 2021 – September 9, 2022
- Population:
- Inclusion: Critically and noncritically ill hospitalized patients with COVID-19
- Exclusions: Not detailed in available trial text
- Intervention: Ivermectin (standard dose, added to standard care)
- Comparator: No ivermectin (standard care)
- Randomization: 81 ivermectin, 69 control (adaptive platform design, no fixed maximum sample size)
- Blinding: Open-label
- Statistical Power & Follow-Up: Bayesian cumulative logistic model; efficacy required ≥99% posterior probability of superiority; futility required <5% probability of ≥20% OR improvement. Primary outcome: respiratory/cardiovascular organ support-free days to day 21 (in-hospital death through day 90 = worst category).
4. Key Results
Stopped for operational futility before any statistical stopping threshold was formally met.
Outcome | Ivermectin | Control | Effect Size | 95% CrI | Posterior Prob. Superiority | Notes |
Organ support-free days, critically ill (n=61) (primary) | Median −1 (IQR −1 to 17) | Median −1 (IQR −1 to 17.25) | Adjusted proportional OR 0.94 | 0.40–2.07 | 44.2% | Clearly neutral |
Organ support-free days, noncritically ill (n=89) | Median 22 (IQR 18.5–22) | Median 22 (IQR 16–22) | Adjusted proportional OR 1.04 | 0.48–2.34 | 53.7% | Neutral |
Hospital survival, critically ill | 35.1% (13/37) | 37.5% (9/24) | Adjusted OR 1.00 | 0.39–2.32 | 50.0% | No difference |
Hospital survival, noncritically ill | 84.1% (37/44) | 77.8% (35/45) | Adjusted OR 1.16 | Not fully specified | — | Not significant |
Note: Very small analyzed sample (61 critically ill, 89 noncritically ill) due to early operational stopping — wide credible intervals compatible with both meaningful benefit and harm.
5. Internal Validity Assessment
- Randomization & Allocation: Randomized within the REMAP-CAP adaptive platform, using a Bayesian cumulative logistic model adjusted for domain eligibility/assignments, site, country, age, sex, and calendar epoch.
- Protocol Adherence & Separation: Very low missingness: no missing primary outcome among analyzed participants.
- Blinding & Detection Bias: Open-label design without placebo — a genuine limitation for an intervention where clinician/patient expectation could plausibly influence co-interventions or outcome ascertainment.
- Missing Data & Sensitivity Analyses: Analysis included concurrent randomization only; missing outcomes excluded (not imputed).
- Overall Internal Validity Conclusion: Limited-to-moderate — the trial was stopped for operational futility (not a formal statistical stopping rule), resulting in a very small analyzed sample (61 and 89 patients in the two strata) with wide credible intervals compatible with both benefit and harm. The adaptive Bayesian framework and low missingness are strengths, but the small sample fundamentally limits the precision of any conclusion.
6. External Validity Assessment
- Population Representativeness: Dominated by South Asian sites (Pakistan, India) with a small number of enrolling sites and one Irish site — important representation of resource-limited practice contexts, but dominance of essentially one country/region limits broader generalizability.
- Practice Context: Low use of invasive ventilation, vasopressors, and IL-6 inhibitors in the enrolled cohort limits extrapolation to many higher-resource ICU settings; standard-dose ivermectin only was tested (no high-dose hospitalized regimen).
- Overall External Validity Conclusion: Limited — small, geographically concentrated sample with a specific (lower-intensity-care) treatment context restricts generalizability to broader, higher-acuity, or differently-resourced hospitalized COVID-19 populations.
7. Strengths & Limitations
Strengths:
- Clinically meaningful primary endpoint incorporating both survival and organ support
- Separate evaluation of critically and noncritically ill strata
- Very low missingness
- Important representation of South Asian sites and resource-limited contexts, historically underrepresented in ivermectin/COVID-19 trial evidence
Limitations:
- Stopped for operational futility before any statistical stopping threshold was met — very small analyzed sample (61 critically ill, 89 noncritically ill)
- Open-label design without placebo
- Wide credible intervals compatible with both benefit and harm
- Dominance of one country/region and small number of sites
- Low use of invasive ventilation/vasopressors/IL-6 inhibitors limits extrapolation to many ICU settings
- Standard-dose ivermectin only — does not address higher-dose hospitalized regimens sometimes used clinically
8. Interpretation & Practice Impact
- Clinical Implications: Per the trial's own conclusion, ivermectin was "unlikely to improve" the primary composite outcome of organ support-free days and hospital survival for hospitalized COVID-19 patients — though the small sample and wide credible intervals mean this should be read as "no clear signal of benefit" rather than a definitive, precise exclusion of any effect.
- Mechanistic Coherence: Consistent with the broader pattern of ivermectin evidence: a 2023 meta-analysis of 40 RCTs (23,243 participants) found no statistically significant mortality benefit in hospitalized patients (RR 0.94, 95% CI 0.74-1.20) or outpatients (RR 0.88, 95% CI 0.55-1.42).
- Systems-Level Takeaway: Reinforces existing guidance against routine ivermectin use for hospitalized COVID-19, while the small sample size means this specific trial adds relatively modest additional precision to an already-large body of neutral evidence.
9. Controversies & Subsequent Evidence
- Editorial Commentary: An accompanying Critical Care Medicine editorial (Maves, "Desperate Times and Good Science: Lessons From REMAP-CAP") reflects on the broader lessons of conducting rigorous trials during a pandemic characterized by intense public and political pressure around unproven therapies.
- Independent Critique: Notably, an independent website (c19early.org) has published detailed methodological criticism of this trial, alleging post-hoc changes to the statistical analysis plan, primary outcome changes, and reporting delays exceeding 600 days, and arguing the trial should be excluded from meta-analyses on these grounds. This handbook reports this critique's existence for balanced disclosure but has not independently verified these specific claims; readers should consult both the primary publication and independent commentary before forming a final view on the trial's conduct.
- Guideline Integration: Consistent with existing international guidance (WHO, IDSA) recommending against routine ivermectin use for COVID-19 outside clinical trials.
10. Summary & Executive Takeaway
Summary: This REMAP-CAP domain trial randomized 81 ivermectin and 69 control hospitalized COVID-19 patients (critically and noncritically ill) across sites in Pakistan, India, and Ireland. The trial was stopped for operational futility with only 61 critically ill and 89 noncritically ill patients analyzed. Organ support-free days and hospital survival did not significantly differ between groups in either stratum (posterior probabilities of superiority 44.2-53.7%).
Overall Takeaway: Ivermectin showed no clear signal of benefit for hospitalized COVID-19 patients in this small, early-terminated trial, consistent with the broader neutral evidence base from dozens of prior RCTs — though the very small sample size and wide credible intervals mean this specific trial's contribution to precision is modest, and readers should be aware of published methodological critique of this trial's conduct and reporting timeline.
11. Bibliography
- Reis G, Silva EASM, Silva DCM, et al; TOGETHER Investigators. Effect of Early Treatment with Ivermectin among Patients with Covid-19. N Engl J Med. 2022;386(18):1721-1731.
- Maves RC. Desperate Times and Good Science: Lessons From REMAP-CAP [editorial]. Crit Care Med. 2026;54(7):1798-1800.